Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC

The growing number of clinical trials testing neoadjuvant immunotherapy with or without chemotherapy has opened up new possibilities for treating locally advanced solid tumors.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

Telisotuzumab vedotin demonstrated promising efficacy and safety in patients with advanced nonsquamous non–small cell lung cancer with high or intermediate c-Met expression.

At 2 separate Case-Based Roundtable events, oncologists discussed important factors that could influence their choice of frontline therapy for a patient with advanced hepatocellular carcinoma.